Johns Hopkins Health Alert
First Drug Approved for Seasonal Depression
Feeling SAD? Wellbutrin XL may help.
The Food and Drug Administration (FDA) has approved Wellbutrin XL (bupropion HCL extended-release tablets) for the prevention of major depressive episodes in people with a history of seasonal affective disorder (SAD). Wellbutrin XL is the first drug officially approved for seasonal affective disorder, which is characterized by recurrent bouts of major depression that coincide with the shorter daylight hours of autumn and winter (thus the nickname "winter depression”).
At this time of year, changes in the amount of daily sunlight cause changes in the body’s internal biological clock, known as circadian rhythm. This rhythm is a 24-hour cycle that affects our eating and sleeping patterns, brain wave activity, hormone production and other biological activities. In some people, less daily sunlight and changes in circadian rhythm can bring about depression. One theory is that the relative lack of sunlight during these times may alter brain levels of certain mood-related chemicals. People with seasonal affective disorder often eat and sleep excessively, crave sugary or starchy foods and have a full remission of seasonal affective disorder in the spring and summer when more daily sunlight is available.
The efficacy of Wellbutrin XL for the prevention of seasonal affective disorder episodes was demonstrated in three double-blind, placebo-controlled trials -- the gold standard of medical research -- in adults with a history of recurrent major depressive disorder in autumn and winter. Treatment for seasonal affective disorder was started before the onset of symptoms in the autumn (September to November) and was discontinued following a two-week taper starting the first week of spring (fourth week of March). In these trials, the percentage of patients who were depression-free at the end of treatment was significantly higher for those on Wellbutrin XL than for those on placebo. Combining data from all three studies, the overall rate of patients depression-free at the end of treatment was 84 percent for those on Wellbutrin XL, compared to 72 percent for those on placebo.
These findings have not surprised psychiatrists and primary care physicians, who have long been using antidepressant drugs off label for treating seasonal affective disorder. But the stamp of approval by the FDA adds credibility to this treatment approach.
Posted in Depression and Anxiety on January 17, 2007
Reviewed June 2011
Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Johns Hopkins Health Alerts Disclaimer
Notify Me
Would you like us to inform you when we post new Depression and Anxiety Health Alerts?
Comments
Health Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the Johns Hopkins editors cannot be answered in this space.
The views expressed here do not constitute medical advice, and do not represent the position of Johns Hopkins Medicine or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.
Post a Comment
Already a subscriber?
Login
New to Johns Hopkins Health Alerts?
Wellbutrin had worked for my SAD so I know it works. I wonder how 72% were able to get better on placebo and only 84% taking Wellbutrin? I would think that 72% persons feeling recovery from a placebo would wonder how many say they are getting better because that is what they think the trial person wishes to hear?
Posted by: Cherat51 | January 31, 2007 2:38 PM